Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program by Roxanne Payne et al.
Payne et al. Journal for ImmunoTherapy of Cancer 2014, 2:13
http://www.immunotherapyofcancer.org/content/2/1/13RESEARCH ARTICLE Open AccessDurable responses and reversible toxicity of
high-dose interleukin-2 treatment of melanoma
and renal cancer in a Community Hospital
Biotherapy Program
Roxanne Payne1, Lyn Glenn1, Helena Hoen1, Beverley Richards1, John W Smith II2, Robert Lufkin2,
Todd S Crocenzi1, Walter J Urba1 and Brendan D Curti1*Abstract
Background: High-dose interleukin-2 (IL-2) has been FDA-approved for over 20 years, but it is offered only at a
small number of centers with expertise in its administration. We analyzed the outcomes of patients receiving
high-dose IL-2 in relation to the severity of toxicity to ascertain if response or survival were adversely affected.
Methods: A retrospective analysis of the outcomes of 500 patients with metastatic renal cell carcinoma (RCC) (n = 186)
or melanoma (n = 314) treated with high-dose IL-2 between 1997 and 2012 at Providence Cancer Center was performed.
IL-2 was administered at a dose of 600,000 international units per kg by IV bolus every 8 hours for up to 14 doses. A second
cycle was administered 16 days after the first and patients with tumor regression could receive additional cycles. Survival
and anti-tumor response were analyzed by diagnosis, severity of toxicity, number of IL-2 cycles and subsequent therapy.
Results: The objective response rate in melanoma was 28% (complete 12% and partial 16%), and in RCC was 24%
(complete 7% and partial 17%). The 1-, 2- and 3-year survivals were 59%, 41% and 31%, for melanoma and 75%, 56% and
44%, for RCC, respectively. The proportion of patients with complete or partial response in both melanoma and RCC was
higher in patients who a) required higher phenylephrine doses to treat hypotension (p < 0.003), b) developed acidosis
(bicarbonate < 19 mmol (p < 0.01)), or c) thrombocytopenia (<50, 50–100, >100,000 platelets; p < 0.025). The proportion
achieving a complete or partial response was greater in patients with melanoma who received 5 or more compared with
4 or fewer IL-2 cycles (p < 0.0001). The incidence of death from IL-2 was less than 1% and was not higher in patients who
required phenylephrine.
Conclusions: High-dose IL-2 can be administered safely; severe toxicity including hypotension is reversible and can be
managed in a community hospital. The tumor response and survival reported here are superior to the published literature
and support treating patients to their individualized maximum tolerated dose. IL-2 should remain part of the treatment
paradigm in selected patients with melanoma and RCC.
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Metastatic melanoma and metastatic RCC are both highly
lethal tumors with a poor prognosis. The incidence and
prevalence of both cancers are increasing in the United
States. In 2013 there are estimated to be greater than
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unless otherwise stated.and approximately 65,000 new diagnoses with 13,500
deaths from RCC. Only 5%-10% of patients survive for
5 years once metastatic disease develops [1].
There have been recent advances in the treatment of
melanoma. Two randomized phase III studies, which
showed improved survival for patients with advanced
melanoma treated with ipilimumab led to the FDA ap-
proval of ipilimumab for first or second-line treatment
of metastatic melanoma in March 2011 [2,3]. Long term
follow-up data has also been reported after ipilimumabtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of patient characteristics, including






Male 187 (60) 138 (74)
Female 127 (40) 48 (26)
Age
Mean (SD) 53.2 (11.9) 57.3 (9.1)
Range 20 -79 30 – 80
ECOG performance status
0 220 (71) 136 (73)
1 85 (27) 47 (25)
2 7 (2) 3 (2)
Sites of metastatic disease
Lymph node 154 (49) 39 (21)
Lung 181 (58) 137 (74)
Liver 96 (31) 31 (17)
Bone 79 (25) 43 (23)
Brain 47 (15) 14 (7)
Subcutaneous 69 (22) 1(1)
Number of metastatic sites
1 42 (13) 61 (33)
2 69 (22) 50 (27)
3 54 (17) 38 (20)
4 149 (48) 37 (20)
Prior treatment
Nephrectomy 2 (1) 162 (87)
Radiation 139 (44) 41 (22)
Chemotherapy 28 (9) 8 (4)
Immunotherapy 119 (38) 9 (5)
VEGF TKI 0 (0) 11 (6)
Other 71 (23) 24 (13)
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Monotherapy with PD-1-directed antibodies and combi-
nations of T-cell check point inhibitors are also showing
significant clinical promise. Nivolumab (anti-PD-1) and
ipilimumab showed an objective response rate of 40% in
patients with metastatic melanoma [5]. Even with the re-
cent FDA approval of ipilimumab showing a 4 month im-
provement in median survival, [2] and targeted agents
such as vemurafenib having a high initial response rate of
approximately 50%, [6,7] 90% of patients with widespread
melanoma die within 5 years using extant therapy.
There has also been significant progress in the develop-
ment of new agents for the treatment of metastatic renal
cancer (RCC). Targeted agents approved for advanced RCC
include sorafenib, sunitinib, pazopanib, temsirolimus, eve-
rolimus and axitinib [8-12]. Even though these agents have
improved treatment of patients with metastatic kidney can-
cer, VEGF-TKI or m-TOR directed therapies are associated
with a median duration of response of approximately
11 months. Median survival reported with VEGF-TKI ther-
apy is generally less than 2 years, although a minority of pa-
tients can achieve control of disease for several years by
using these agents in sequence. Currently available oral
agents for RCC do not cure metastatic disease.
Interleukin-2 (IL-2) is a cytokine produced by activated
T cells that increases proliferation and activation of cyto-
toxic T-cells, NK cells and monocytes [13]. The antitumor
activity of recombinant IL-2 in preclinical and clinical set-
tings) led to 7 pivotal clinical trials and FDA approval for
patients with metastatic kidney cancer in 1992 and meta-
static melanoma in 1998. Overall response was 16% in
melanoma and 15% in RCC. Long-term survival was also
demonstrated in a minority of patients with melanoma
and RCC; however, no prospective randomized phase 3
studies have been performed with IL-2 showing a survival
benefit. Despite the absence of phase 3 studies, IL-2 was
approved because of durable responses were observed,
and at the time of approval there were no other better
therapeutic alternatives in melanoma and RCC. IL-2 tox-
icity depends on the dose, route and duration of adminis-
tration. High-dose bolus IL-2 has systemic effects that can
impact all organ systems profoundly. These effects are due
to a vascular leak syndrome initiated by circulating cyto-
kines, inducible nitric oxide, and activation of neutrophils,
complement and the endothelium [14,15]. In particular,
patients may experience profound hypotension, acute re-
nal injury, acidosis and other metabolic disturbances. The
use of high-dose bolus IL-2 remains limited because of its
toxicity and relatively low response rates; however, the
durable responses are clinically meaningful and IL-2 has a
place in recently published treatment guidelines for both
melanoma and renal cancer [16-18].
We report on the clinical outcomes of 500 patients
with melanoma and RCC treated with high-dose IL-2 atour cancer center. The response and survival we observed
is superior to historical data for IL-2 and our analysis sup-
ports that treating patients to their individualized max-
imum tolerated dose (MTD) enhances response. We also
demonstrate that there is no adverse influence on survival
or response by the severity of toxicity.
Results
Patient characteristics
The 1601 admissions in this retrospective analysis repre-
sent 500 consecutive patients treated at the Providence
Cancer Center Biotherapy Program from 1997 to 2012 are
summarized in Table 1. Seven other patients in our data-
base were excluded due to missing response information
or IL-2 offered in the adjuvant setting via a clinical trial.
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with prior immunotherapy received interferon in the ad-
juvant setting. Six patients with melanoma received ipili-
mumab and 3 received vemurafenib before IL-2. Of the
patients with melanoma, two patients had choroidal and
14 mucosal primary sites. Twenty-four patients had an
LDH >500. Two patients with biopsy proven metastatic
melanoma also had a nephrectomy, one individual had a
previous history of localized renal cancer treated surgi-
cally and the other had melanoma metastatic to the kid-
ney in whom nephrectomy was performed for palliation.
Patients with brain metastases could receive IL-2 if they
were treated with surgery, radiation or the combination,
and were asymptomatic and off steroids. The distribu-
tion of metastatic sites, age and gender were as expected
based on the natural history of these malignancies. Func-
tional status was normal (ECOG 0) for > 70% of patients
who received high dose IL-2 on our Biotherapy Service.
Clinical outcomes
Median follow-up was 4.7 years and ranged from 1 month
to 10.8 years for patients with melanoma. For patients
with RCC, median follow-up was 7.1 years and ranged
from 1 month to 15 years at the time of the database ana-
lysis. The objective response rate in melanoma was 28%
(complete 12% (n = 37) and partial 16% (n = 49), and in
RCC was 24% (complete 7% (n = 12) and partial 17% (n =
32)). Stable disease was observed in 51 patients with mel-
anoma and 54 with renal cancer. We observed melanoma
regression in patients with poor clinical prognostic indica-
tors. For instance, among the 24 patients who had an
LDH > 500 IU there were 2 CR, 2 PR and 2 SD. Table 2
shows the percent overall survival for years 1 – 5 after
treatment. Figure 1 shows survival by response group. The
median survival of patients achieving a complete response
(CR) was not reached in melanoma or RCC. For patients
with partial response (PR), stable disease (SD) or progres-
sive disease (PD), the median survivals were 40.7, 32.6 and
7.7 months in melanoma, and 48.1, 57.2 and 12.7 in RCC,
respectively. The survival of patients with PR or SD and
subsequent progression after IL-2 was influenced by other
systemic therapies (see below).
Responses were analyzed by the severity of toxicity. We
chose to perform this analysis to ascertain if either response
or survival was influenced by the main dose-limiting tox-
icity of IL-2, namely, hypotension, occurring during any
treatment cycle. Phenylephrine is the pressor agent used
routinely on our Biotherapy Service and pressor dose isTable 2 Percent survival by year and diagnosis after IL-2
Year 1 2 3 4 5
Melanoma 59 41 31 24 23
Renal cancer 75 56 44 39 31titrated to maintain blood pressure greater than minimum
tolerated blood pressure (MTBP) (see Methods for further
details on pressor titration). For patients who required
phenylephrine, patients were divided into two groups by
maximum dose required to maintain MTBP. Phenylephrine
doses <200 mcg/min are generally considered standard in
the management of hypotension while doses > 200 mcg/
min are considered higher than usual practice [19]. Figure 2
depicts the percentage of patients responding by phenyl-
ephrine requirement.
In both melanoma and RCC, the proportion of patients
with CR and PR increased significantly with increasing
amounts of phenylephrine support of 0, >0-200, and >200
mcg/min (p = 0.003 and 0.0003, for the linear trend in re-
sponse across phenylephrine dose groups for melanoma
and RCC, respectively). Figure 3 shows survival by phenyl-
ephrine requirement and diagnosis. Survival was not di-
minished by requirement for pressor support, even at the
highest levels, during IL-2. Since response occurred in a
higher proportion of patients requiring phenylephrine, sur-
vival was also statistically significantly better in both mel-
anoma (p = 0.018) and renal cancer (p = 0.007), compared
to patients who required no pressor support. A similar
analysis was done adjusting the phenylephrine dose by pa-
tient weight (mcg/kg/min) and there was no difference in
the response or survival results as summarized above.
Metabolic acidosis defined by decreased serum bicar-
bonate levels is another severe IL-2-related toxicity that
can arise from lactic acid production by proliferating T
cells [20]. The acidosis is exacerbated by compromised
homeostatic mechanisms from decreased hepatic and
renal function during IL-2. Acidosis can also result from
poor tissue perfusion during episodes of hypotension.
Due to our management strategy of repleting bicarbon-
ate when serum levels were less than 20 mmol, the ma-
jority of patients achieved normal serum bicarbonate
levels within 12 hours after starting repletion. Table 3
shows response by bicarbonate nadir. Complete and par-
tial response rates were significantly greater in patients
with bicarbonate in the 15–19 mmol range in melanoma
(p = 0.010) and in RCC (p = 0.001).
Others have reported that thrombocytopenia correlates
with response to high-dose IL-2 [14,21]. We analyzed our
results according to the platelet nadir during any treat-
ment cycle. In both melanoma and RCC there was a sta-
tistically significant linear trend between achieving CR or
PR and lower platelets counts of < 50,000 cells/mm3;
50,000-100,000; compared to > 100,000 (p = 0.024 and p =
0.022 for melanoma and RCC, respectively).
There were 5 deaths that occurred during IL-2 therapy
in the hospital. Three of the deaths were in patients who
were not hypotensive, while 2 patients who died were
hypotensive during their IL-2 hospitalization and re-
quired phenylephrine at a dose >200 mcg/min; however,
A B
C D
Figure 1 Kaplan-Meier (product limit) survival for melanoma (A) and RCC (B). Survival by best response as assessed by the treating
physician in melanoma (C) and RCC (D).
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occurred. Two deaths were attributable to severe IL-2 tox-
icities (pulmonary capillary leak (n = 1) and neurocortical
toxicity (n = 1)). The other deaths were from progressive
disease (n = 2) and an adverse event unrelated to IL-2 (air
embolism from a patient who removed the central venous
catheter without other mental status changes (n = 1)). No
patient died from toxicity related to phenylephrine. Two















Figure 2 Percent response by phenylephrine dose range in melanomBoth patients survived the operation and were discharged
from the hospital.
The maximum number of IL-2 treatment cycles is gen-
erally 6 for responding patients due to the earlier onset
and severity of toxicities that necessitate holding IL-2
doses. Each cycle is defined as the 5-day hospital admis-
sion during which IL-2 is administered. Two cycles com-
prise 1 course of IL-2 (see Methods for further details).













a (A) and RCC (B).
Figure 3 Survival by maximum phenylephrine pressor requirement (in mcg/min) in melanoma (A) and RCC (B).
Table 4 Responders’ median number of IL-2 doses by
cycle and diagnosis*
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shows the general downward trend in the median number
of IL-2 doses administered per treatment cycle.
The mean number of IL-2 doses in the first 2 cycles in
patients who had a best overall response of CR or PR ver-
sus SD or PD was similar (melanoma responder vs non-
responder mean = 21.1 SD = 3.7 vs mean = 19.5 SD = 4.3
and RCC mean = 18.5, SD = 3.7 vs mean = 17.7 SD = 4.7).
Although 6 IL-2 cycles is a practical maximum for patient
tolerability, there was also variation in clinical practice
among physicians and patient preferences for receiving cy-
cles 5 and 6 if ongoing response was manifest after 4 cy-
cles. Figure 4 shows overall survival by the maximum
number of cycles administered in melanoma and RCC of
the patients that received at least 4 cycles of IL-2. Survival
rates were greater for patients with melanoma who re-
ceived >4 versus 4 cycles (n = 58, 74; p < 0.0001), but there
was no difference in RCC (n=49, 30; p = 0.39).
One of the observations in early clinical trials of IL-2
was that some partial as well as complete responses were
durable without the administration of additional systemic
therapy. We also wanted to characterize the survival of pa-
tients who received cancer treatment after IL-2. We had
treatment follow-up data for 399 patients (252 with mel-
anoma and 147 with RCC) after completion of IL-2 and
survival data for all patients. No additional therapy wasTable 3 Response in melanoma and RCC by
bicarbonate nadir
Melanoma Renal cell carcinoma
Bicarbonate
(mmol)
<15 15-19 >19 <15 15-19 >19
Total N (%) 8 (100) 258 (100) 45 (100) 10 (100) 152 (100) 20 (100)
CR, PR 1 (13) 80 (31) 5 (11) 6 (60) 37 (24) 1 (5)
SD, PD 7 (88) 178 (69) 40 (89) 4 (40) 115 (76) 19 (95)needed in 21% of patients with melanoma (53/252) and
22% in RCC (33/147). Table 5 depicts the best overall re-
sponse by diagnosis for the patients who required no fur-
ther medical therapy. Among these patients, only one
death has been observed in a patient with RCC. For pa-
tients who went on to receive systemic medical therapy
after IL-2, the median survival from start of IL-2 therapy
was 18.4 months in patients with melanoma and 27.0 months
in RCC. The median time to starting a new treatment after
IL-2 was 3 and 5.1 months for melanoma and renal cancer,
respectively. In patients with melanoma who received subse-
quent therapy, 44 were treated with ipilimumab and 6 with
vemurafenib. The median survival of patients who enrolled
in palliative care or hospice or who declined further medical
therapy after IL-2 (due to disease progression) was 3.3
and 2.4 months for patients with melanoma and RCC,
respectively.
Discussion
High-dose IL-2 has been available to treat patients with
melanoma and renal cancer since the 1990’s. Despite
the fact that long-term disease-free survival is seen in
some patients, there are only approximately 100 cancerCycle Melanoma Renal cancer
N Median # doses N Median # doses
1 86 12 44 11
2 86 10 44 8
3 84 10 43 9
4 84 7 43 5
5 58 8 23 6
6 55 4 18 4
*One responding patient with RCC received 8 cycles.
Figure 4 Survival by number of IL-2 cycles in melanoma (A) and RCC (B).
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concerns about toxicity, cost and doubts about efficacy.
The skepticism about efficacy is a consequence of the
original clinical development of IL-2 during which a ran-
domized phase III study to prove there was a survival
benefit compared to other treatments was never per-
formed. The response rate and survival of patients with
melanoma and RCC with high-dose IL-2 monotherapy
reported here is comparable or superior to that de-
scribed in other studies [14,22,23]. The patients with
melanoma and RCC who had stable disease as their best
response after IL-2 also had clinically significant sur-
vivals. Stable disease was not generally reported as an
outcome in the 1980’s and 1990’s when the first clinical
reports of IL-2 were published in the medical literature.
It has been appreciated more recently that patients who
have stable disease after immunotherapy can have clinic-
ally meaningful benefit from therapy. This has been il-
lustrated extensively with ipilimumab in patients with
melanoma [2,3,24]. The objective response among the
patients who required no further therapy for their mel-
anoma or RCC after IL-2 was predominantly CR or PR;
however, some individuals had SD and a few PD. The in-
dividuals with PD on initial scans had minor radio-
graphic abnormalities that at the time of evaluation were
interpreted as cancer progression, but in retrospect were
likely inflammatory changes. To our knowledge there
are no long-term follow-up studies on IL-2 clinical out-
comes published in peer-reviewed literature in the lastTable 5 Best overall radiographic response for patients
who did not require additional systemic therapy
CR PR SD PD Total
Melanoma 27 17 7 2 53
Renal cancer 9 11 10 3 33decade. The 3-year survival of 31% we report in melan-
oma is greater than the 3-year survival reported after ipi-
limumab of 16% in one study [24]. A larger retrospective
study reported a 5-year survival of 22% after ipilimumab,
comparable to the 23% reported in our IL-2 patients [4].
Similarly, the 3-year survival in RCC of 44% is greater
than that reported with VEGFTKI agents, for which the
3-year survival is 20 – 30% [12,25]. Although we de-
scribe a single institution experience, the total number
of patients in this report is greater than other IL-2
single- or multi-institution studies in the medical litera-
ture. We believe these findings are significant in light of
the recent strong interest in immunotherapy and the
knowledge that the objective response rates for T-cell di-
rected antibody monotherapy appear to be between 10 –
30%, which are comparable to our findings with IL-2.
We chose to examine the outcomes of our IL-2 pa-
tients in relation to hypotension, which is the main
dose-limiting toxicity for this treatment. This perspective
is the reverse of the paradigm used to assess most other
medical treatments. Most oncologic agents are devel-
oped using phase I dose escalation studies with the pri-
mary objective of finding a tolerable and biologically
active dose. The logic behind this drug development
paradigm is that toxicity limits dosing, and limited dos-
ing will decrease the efficacy of the agent due to de-
creased dose intensity. In addition, toxicity could also
result in mortality or significant morbidity that would
diminish long-term survival. For biologic agents that
have a mechanism of action inseparable from the physi-
ology of immune activation, this paradigm may not be
valid. We show in our IL-2 population that there is im-
proved response probability and survival in patients who
experienced dose-limiting hypotension requiring high-
dose phenylephrine pressor support. We are not imply-
ing a direct causal link between hypotension and tumor
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ized MTD with IL-2 results in durable remissions. In
addition, our findings support that survival and objective
response are not compromised by toxicity. There is one
previous study with findings similar to ours showing a
favorable correlation with response and IL-2-induced hy-
potension in melanoma patients [26]. The incidence of
death reported here is comparable to other reports in the
medical literature on IL-2 [13]. Others have noted that
there may be an adverse interaction between prior treat-
ment with VEGF-TKI therapy and interleukin-2 cardiac
toxicity in patients with metastatic renal cancer [27]. There
was no discernible difference in the severity or frequency of
cardiac or other IL-2-related toxicities in the 6% of patients
with RCC with previous VEGF-TKI described here. None
of the deaths reported in this retrospective study occurred
in patients with prior VEGF-TKI treatment.
At many immunotherapy centers, IL-2 is given in an
intensive care unit setting, and multiple pressors are
used to manage hypotension. Although the management
of patients receiving IL-2 is complex, scheduling and ad-
ministering cancer therapy in the ICU often strains
scarce hospital resources, the patient’s care is transferred
to a team that does not have extensive experience with
cancer patients or specifically with IL-2. At our can-
cer center we administer IL-2 on the general oncology
in-patient service, but have the ability to administer phenyl-
ephrine and place patients on continuous cardiac monitor-
ing when needed. We manage IL-2 induced hypotension
with phenylephrine because it is an alpha-adrenergic recep-
tor agonist that has much less beta-adrenergic effect than
dopamine or norepinephrine [28]. IL-2 can also cause
tachydysrhythmias, so avoiding inotropes with the ability
to increase heart rate is desirable. The general teaching in
critical care medicine is that phenylephrine doses greater
than 200 mcg/min (2 mcg/kg/min) do not confer signifi-
cant additional inotropy; however, there is only one dose–
response study in septic surgical patients in the recent
medical literature [29]. We have acquired significant ex-
perience using phenylephrine at high doses (up to 5 mcg/
kg/min) to manage IL-2-induced hypotension and it is
well tolerated in this patient population preselected to
have normal cardiopulmonary reserve at baseline.
The optimal number of IL-2 cycles to induce durable
responses has not been defined in previous clinical trials.
Our retrospective study suggests that responding pa-
tients with melanoma have enhanced long-term re-
sponses if they receive >4 IL-2 cycles; however, 4 cycles
may be sufficient in patients with RCC. There are selec-
tion biases inherent in this retrospective analysis and de-
termining the optimal number of IL-2 cycles could only
be answered definitively in a randomized trial comparing
4 versus 6 cycles in responding patients with long-term
follow-up. However, if there was no benefit of > 4 cyclesin patients with melanoma, one might have expected the
survival to be equivalent between these groups.
Although there are many newer agents that can be
used to treat metastatic melanoma and renal cell carcin-
oma, it is our practice that IL-2 should be offered in the
first or second line of therapy for patients who have nor-
mal baseline cardiopulmonary status with the goal of
achieving durable regressions. In this retrospective ana-
lysis, there are 53 patients with melanoma and 33 with
RCC who remain alive, free of disease and have not re-
quired additional systemic therapy. Although some of
these patients will likely need systemic therapy in the fu-
ture, at a minimum, the delay in the need for medical ther-
apy will allow the development of more effective agents
that can be offered when needed. Many of our patients
who had disease progression after IL-2 as first line therapy
participated in clinical trials for second or third line ther-
apy. For melanoma, clinical trials using T-cell directed
antibodies including ipilimumab and anti-PD-1 were of-
fered. In renal cancer, treatment after IL-2 was most com-
monly a VEGF-TKI agent via clinical trial or standard of
care. We believe these subsequent therapies had a favor-
able influence on the survival data presented here.
IL-2 can be administered to patients whose cancers
have progressed after other agents. We believe this ap-
proach is not optimal especially in patients with renal
cancer as durable remissions are rarely achieved with
TKI therapy, and the patient’s performance status is
more likely to decline with each successive systemic
treatment, thus the opportunity to use IL-2 can be lost.
The correspondence between good performance status
(ECOG 0–1) and IL-2 response has also been observed
by others [30,31]. This retrospective study confirms that
IL-2 can be administered safely in the community set-
ting, that severe toxicities can be managed with a well-
trained biotherapy team and that excellent clinical results
with durable responses can be achieved in melanoma and
RCC. Our observations support that patients who receive
high-dose IL-2 should be treated to their individualized
MTD to derive the greatest clinical benefit from this
immunotherapy.Conclusions
High-dose IL-2 can be administered safely, severe toxicity
is reversible and does not compromise objective response
rate. The tumor response and survival reported here after
IL-2 are superior to the published literature and confirms
that durable regressions of disease are achievable in pa-
tients with advanced melanoma and renal cancer. Our
findings also support the practice of treating patients to
their individualized maximum tolerated IL-2 dose. IL-2
should remain part of the treatment paradigm in selected
patients with melanoma and RCC.
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Selection of patients
All patients had a diagnosis of either metastatic RCC or
metastatic melanoma and had signed informed consent
for inclusion in the Providence Cancer Center Biotherapy
Program database between 1997 and December 2012. All
1601 admissions during this time interval were examined.
Patients who receive high-dose IL-2 must first have a pre-
treatment evaluation including pulmonary function test-
ing, laboratory tests of hepatic and renal function and
cardiac stress testing when applicable, to assess their abi-
lity to withstand the toxicity of treatment. A brain MRI or
other brain imaging is also included in the evaluation of
patients with melanoma or RCC patients with symptoms
suggestive of CNS metastases. Patients with treated brain
metastases received IL-2 therapy after completing radi-
ation and/or surgery, and were off corticosteroids for a
minimum of 2 weeks. Patients with autoimmune disease
requiring active therapy were excluded. Interleukin-2
Regimen: Patients were admitted to the medical oncology
unit of Providence Portland Medical Center. The care
team consists of a biotherapy attending physician, nurse
practitioner and oncology certified staff nurses who have
received specific didactic training and supervised pre-
ceptor experiences in the management of patients receiv-
ing high-dose IL-2 and in the titration of vasopressors.
EKG telemetry, oximetry and continuous blood pressure
monitoring is readily available for patients with hemody-
namic instability. IL-2 (Prometheus Pharmaceuticals, San
Diego, CA) was administered at 600,000 international
units/kg/dose by IV bolus every 8 hours for a maximum
of 14 doses followed by a 16-day rest period, followed by a
repeat cycle. IL-2 doses were held for severe toxicity, but
there was no reduction in the calculated amount per dose.
Additional IL-2 was offered to patients having regression
of disease. One patient received 8 cycles, but 6 cycles
was maximum offered to responding patients. Additional
courses (one course of therapy is defined as two cycles) of
high-dose IL-2 were administered on average, within 9
weeks of completion of the prior course. Additional time
off between courses of therapy was considered on a case-
by-case basis to allow adequate recovery.
All antihypertensive medications were discontinued
before hospital admission. A triple lumen central venous
catheter was placed at the beginning of each cycle of
IL-2 and removed before hospital discharge. Patients
received antibiotic prophylaxis to reduce infection. Pa-
tients were routinely monitored and received supportive
care for management of toxicities experienced as a con-
sequence of therapy. We used our Biotherapy Program
standard operating procedures for management of IL-2
toxicities, which are based on other published guidelines,
but differ significantly in that high-dose phenylephrine is
used when needed and IL-2 doses are rarely held foracute renal insufficiency or metabolic acidosis [32]. Be-
fore starting IL-2, a MTBP was defined, usually systolic
85–90 mmHg, based on a clinical judgment of the pa-
tient’s physiological reserve as indicated by ETT and
baseline blood pressure. If the patient’s systolic BP fell
below the MTBP, a normal saline fluid bolus was admin-
istered over 15 minutes. If the blood pressure did not
rise to > MTBP, then the NS bolus was repeated up to
two additional times. If the blood pressure remained
below the MTBP after 3 NS boluses, treatment with
phenylephrine was initiated. A small number of patients
in the database also received dopamine pressor support
in addition to phenylephrine, but are not reported
separately.
Titration of phenylephrine
The initial phenylephrine dose was 40 mcg/min with
rapid titration in increments of 25–50 mcg every 5–15
minutes to achieve the MTBP. The minimum amount of
phenylephrine was then used to maintain the MTBP. Pa-
tients who required more than 200 mcg/min sometimes
received additional interventions such as fluid boluses. If
the phenylephrine dose exceeded 5 mcg/kg/min to
maintain the MTBP, the patient was transferred to the
ICU, where additional vasopressors (e.g.: norepineph-
rine) or other interventions were implemented as dic-
tated by the patient’s clinical needs. Doses of IL-2 were
held during hypotensive episodes if the phenylephrine
dose was ≥ 100 mcg and/or if the titration requirement
for phenylephrine was increasing in the hour prior to
the planned IL-2 dose. IL-2 was resumed if the dose of
phenylephrine was <100 mcg/min, the titration trend
was downward, and there were no other dose-limiting
toxicities. IL-2 was not generally discontinued for
phenylephrine doses peaking >200 mcg/min in contrast
to other centers [32].
Tumor response
Computed tomography was the most commonly used
imaging modality to assess tumor response and was usu-
ally obtained after every 2 IL-2 cycles and every 3 months
for the first year after IL-2 was completed. Imaging ob-
tained after this interval was at the discretion of the at-
tending physician and the clinical circumstances of the
patient. Response evaluation criteria for solid tumors
(RECIST) and the assessment of the attending physician
were used to categorize response [33]. Complete re-
sponse (CR) was defined as the complete disappearance
of all target and non-target lesions. Partial response (PR)
was defined as a 30% or greater decrease in the sum of
the maximum diameter of target lesions. Progressive dis-
ease (PD) was defined as a 20% or greater increase in
the sum of the largest diameter of target lesions or the
appearance of new lesions. Stable disease (SD) was
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other response designations. Patients with minor regres-
sion (e.g.: tumor response not sufficient to qualify for
PR) could receive additional IL-2 cycles if clinical benefit
was present as assessed by the attending physician. Radi-
ology reports were available for all patients and re-
sponses were reviewed by the biotherapy attending
physician (BDC), but were not reviewed by an independ-
ent radiologist for this retrospective analysis.Statistical analysis
Analyses were carried out separately for melanoma and
renal cancer patients due to marginal evidence of inter-
action effects between measures and cancer type for both
best response and survival outcomes. Each interaction was
tested in a separate model. For best response, logistic re-
gression was used, and for survival, Cox proportional
hazards was used. Best response was determined from as-
sessment across all scans done after completing each IL-2
course, typically about 4 weeks later. Association between
best response (CR+PR, SD+PD) and phenylephrine dose
group (none, >0 – 200, >200 mcg/min; none, >0 – 2.5, >2.5
mcg/kg/min), platelet nadir group (<50, 50–100, >100
thousand), bicarbonate nadir group (<15, 15–19, >19
mmol/L), and IL-2 cycles [1-8] were tested with the
Cochran- Armitage test for trend. Exact Cochran-Armitage
test was used for bicarbonate nadir in the renal group due
to small expected number of observations, and Fisher’s
Exact in the melanoma group due to small expected num-
ber of observations and non-linear association with re-
sponse. Effect of phenylephrine dose rate group was
analyzed both with and without adjustment for pa-
tient weight. Time from start of first IL-2 dose to
death was analyzed using survival analysis. Median
duration of follow-up was modeled with deaths cen-
sored. Log rank tests were used to test for differences in
Kaplan-Meier (product limit) survival estimates among
phenylephrine dose groups, with and without adjustment
for body weight, groups of number of IL-2 cycles, and
whether subsequent treatment was received after IL-2.
Analyses were performed using SAS 9.3 (SAS Institute
Inc., Cary, NC).Abbreviations
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